Connect Sign In
3004572
Multiple Endocrine Neoplasia Type 2 (MEN2), RET Sequencing
MEN2 NGS
Ordering Recommendation
Diagnostic and predictive testing for multiple endocrine neoplasia type 2 (MEN2) syndrome caused by pathogenic variants in the RET gene.
New York DOH Approval Status
Testing is not New York state approved. Specimens from New York clients will be sent out to a New York state-approved laboratory.
Specimen Required
Patient Preparation
Collect
Lavender or pink (EDTA) or yellow (ACD solution A or B).
New York State Clients: Lavender (EDTA)
Specimen Preparation
Transport 3 mL whole blood. (Min: 2 mL)
New York State Clients: 5 mL (Min: 2 mL)
Storage/Transport Temperature
Unacceptable Conditions
Serum or plasma; grossly hemolyzed or frozen specimens; saliva, buccal brush, or swab; FFPE tissue.
Remarks
Stability
Ambient: 72 hours; Refrigerated: 2 weeks; Frozen: Unacceptable
New York State Clients: Ambient: 24 hours; Refrigerated: 1 week; Frozen: Unacceptable
Methodology
Massively Parallel Sequencing
Performed
Varies
Reported
10-15 days
Reference Interval
By report
Interpretive Data
Refer to report.
Compliance Category
Laboratory Developed Test (LDT)
Note
Gene Tested: RET (NM_020975)
Hotline History
Hotline History
Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
N/A
CPT Codes
81406
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 3004573 | MEN2 Specimen | 31208-2 |
| 3004574 | MEN2 Interp |
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
- familial medullary thyroid cancer (FMTC)
- MEN2A
- MEN2B
Multiple Endocrine Neoplasia Type 2 (MEN2), RET Sequencing
